Nektar Therapeutics (NKTR) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Nektar Therapeutics (NKTR) Bundle
Streamline your analysis and improve precision with our NKTR (Nektar Therapeutics) DCF Calculator! Equipped with real data from Nektar and customizable assumptions, this tool enables you to forecast, evaluate, and value NKTR like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.6 | 152.9 | 101.9 | 92.1 | 90.1 | 87.5 | 84.9 | 82.4 | 80.0 | 77.7 |
| Revenue Growth, % | 0 | 33.41 | -33.36 | -9.67 | -2.1 | -2.93 | -2.93 | -2.93 | -2.93 | -2.93 |
| EBITDA | -382.7 | -394.3 | -463.0 | -323.9 | -243.1 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| EBITDA, % | -333.89 | -257.87 | -454.3 | -351.82 | -269.75 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 11.0 | 12.5 | 13.0 | 12.2 | 7.8 | 9.2 | 8.9 | 8.6 | 8.4 | 8.1 |
| Depreciation, % | 9.6 | 8.17 | 12.76 | 13.25 | 8.67 | 10.49 | 10.49 | 10.49 | 10.49 | 10.49 |
| EBIT | -393.7 | -406.8 | -476.0 | -336.1 | -250.9 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| EBIT, % | -343.49 | -266.05 | -467.06 | -365.08 | -278.42 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 1,324.9 | 1,061.9 | 734.0 | 505.0 | 303.6 | 87.5 | 84.9 | 82.4 | 80.0 | 77.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 36.8 | 38.9 | 22.5 | 6.0 | 2.3 | 15.5 | 15.0 | 14.6 | 14.2 | 13.8 |
| Account Receivables, % | 32.11 | 25.43 | 22.07 | 6.5 | 2.5 | 17.72 | 17.72 | 17.72 | 17.72 | 17.72 |
| Inventories | 12.7 | 15.3 | 15.8 | 19.2 | 16.1 | 13.2 | 12.8 | 12.4 | 12.0 | 11.7 |
| Inventories, % | 11.05 | 10 | 15.51 | 20.86 | 17.87 | 15.06 | 15.06 | 15.06 | 15.06 | 15.06 |
| Accounts Payable | 19.2 | 22.1 | 9.7 | 13.0 | 9.8 | 11.5 | 11.2 | 10.9 | 10.5 | 10.2 |
| Accounts Payable, % | 16.78 | 14.48 | 9.56 | 14.1 | 10.93 | 13.17 | 13.17 | 13.17 | 13.17 | 13.17 |
| Capital Expenditure | -26.3 | -7.3 | -15.0 | -5.7 | -.9 | -8.7 | -8.4 | -8.2 | -7.9 | -7.7 |
| Capital Expenditure, % | -22.93 | -4.75 | -14.71 | -6.17 | -0.95981 | -9.9 | -9.9 | -9.9 | -9.9 | -9.9 |
| Tax Rate, % | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 | 0.07239662 |
| EBITAT | -394.2 | -407.3 | -476.5 | -339.0 | -250.7 | -87.5 | -84.9 | -82.4 | -80.0 | -77.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -439.8 | -403.8 | -475.0 | -316.2 | -240.1 | -95.6 | -83.9 | -81.5 | -79.1 | -76.8 |
| WACC, % | 9.39 | 9.39 | 9.39 | 9.39 | 9.38 | 9.38 | 9.38 | 9.38 | 9.38 | 9.38 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -324.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -78 | |||||||||
| Terminal Value | -1,060 | |||||||||
| Present Terminal Value | -677 | |||||||||
| Enterprise Value | -1,001 | |||||||||
| Net Debt | 210 | |||||||||
| Equity Value | -1,211 | |||||||||
| Diluted Shares Outstanding, MM | 190 | |||||||||
| Equity Value Per Share | -6.37 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NKTR financials.
- Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Quickly observe the effect of your inputs on Nektar Therapeutics’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Pre-Loaded Data: Nektar Therapeutics’ historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Edit WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: See Nektar Therapeutics’ intrinsic value recalculate in real time.
- Clear Visual Outputs: Dashboard charts display valuation results and key metrics.
- Built for Accuracy: A professional tool for analysts, investors, and finance experts.
How It Works
- 1. Open the Template: Download and open the Excel file containing Nektar Therapeutics (NKTR) preloaded data.
- 2. Edit Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV for Nektar Therapeutics (NKTR).
- 4. Test Scenarios: Evaluate various forecasts to explore different valuation outcomes for Nektar Therapeutics (NKTR).
- 5. Use with Confidence: Present professional valuation insights to support your investment decisions regarding Nektar Therapeutics (NKTR).
Why Choose This Calculator for Nektar Therapeutics (NKTR)?
- Accurate Data: Up-to-date Nektar Therapeutics financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants focused on Nektar Therapeutics.
- User-Friendly: Easy-to-navigate design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Nektar Therapeutics (NKTR) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Nektar Therapeutics (NKTR).
- Consultants: Deliver professional valuation insights on Nektar Therapeutics (NKTR) to clients quickly and accurately.
- Business Owners: Understand how biopharmaceutical companies like Nektar Therapeutics (NKTR) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Nektar Therapeutics (NKTR).
What the Template Contains
- Pre-Filled DCF Model: Nektar Therapeutics’ (NKTR) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Nektar Therapeutics’ (NKTR) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.